The U.S. Food & Drug Administration (FDA) is suggesting that osteoporosis patients limit their use of a popular line of drugs which includes Fosamax, Actonel and Boniva to between three [...]
Fosavance Information
FDA Recommends Bisphosphonate Regimens of 3 to 5 Years Max
New Research Confirms Bisphosphonate Bone Fracture Risk
A new study has confirmed a mountain of previous research identifying a link between a specific class of osteoporosis medication and an increased risk for low-trauma bone fractures, which usually [...]
FDA Panel Recommends Stronger Warnings for Bisphosphonates
September 12, 2011 – Last week, two FDA advisory panels recommended increasing the warnings on labels of a number of popular bisphosphonate drugs taken by millions of American women to [...]
FDA Panel to Review Bisphosphonate Bone Fracture Side Effects
On September 9, an FDA advisory committee is set to meet to discuss the growing number of serious side effects reported in connection with Fosamax and other bisphosphonate medications. These [...]
Fosavance Lawsuit
Our Fosavance lawyers are now investigating lawsuits on behalf of patients who have experienced femur fractures and other serious injuries after taking Fosavance, a drug prescribed for the treatment of [...]
